Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Huan Zhou
The First Affiliated Hospital of Bengbu Medical University
Study Director - Huan Zhou, Dr
The First Affiliated Hospital of Bengbu Medical University
Principal Investigator - Lin Zhen Zhang, Dr
Shanghai 6th People's Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
- Shanghai Sixth People'S Hospital
Shanghai, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Sept 2025
- Primary completion
- 6 Sept 2026
- Completion
- 6 Sept 2027
- Last update posted
- 17 Sept 2025
- Registered enrollment
- 44
- Registry id
- NCT07178327
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.